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Post-exposure risk assessment of chemical and environmental stressors is a public health challenge. Linking exposure to health
outcomes is a 4-step process: exposure assessment, hazard identiﬁcation, dose response assessment, and risk characterization.
This process is increasingly adopting “in silico” tools such as physiologically based pharmacokinetic (PBPK) models to ﬁne-
tune exposure assessments and determine internal doses in target organs/tissues. Many excellent PBPK models have been
developed. But most, because of their scientiﬁc sophistication, have found limited ﬁeld application—health assessors rarely use
them. Over the years, government agencies, stakeholders/partners, and the scientiﬁc community have attempted to use these
models or their underlying principles in combination with other practical procedures. During the past two decades, through
cooperative agreements and contracts at several research and higher education institutions, ATSDR funded translational research
has encouraged the use of various types of models. Such collaborative eﬀorts have led to the development and use of transparent
and user-friendly models. The “human PBPK model toolkit” is one such project. While not necessarily state of the art, this
toolkit is suﬃciently accurate for screening purposes. Highlighted in this paper are some selected examples of environmental
and occupational exposure assessments of chemicals and their mixtures.
1.Background
Asindustrialsocietyinhabitants,weareexposedtohundreds
of chemicals and to an increasing number of chemical
combinations, as mixtures. Exposure to multiple chemicals
simultaneously or sequentially is the rule rather than the
exception [1]. Chemical risk assessments estimate public
health consequences from exposure—speciﬁcally, exposure
to environmental, occupational, or therapeutic chemicals.
Most often, estimates of unintentional exposures are based
on imprecise metrics of external (air, water, and soil) con-
centrations and default exposure factors. Chemical exposure
assessment thus continues to challenge public health and
environmental protection.
Evaluation of human exposure data in the context of
publichealth(i.e.,thelinkingofexposurestohealthoutcome
through the establishment of the cause-eﬀect relationship)
is a complex process. To establish this relationship, several
traditional programs have been used, including health
surveillance and disease registries. Through these programs,
researchers closely monitor chemical releases in the envi-
ronment and conduct health studies. When exposed cohorts
of human populations are identiﬁed, disease registries are
established. The cause-eﬀect relationship brings together
several biochemical and molecular processes such as nature
of the exposures, pharmacokinetics/pharmacodynamics of
the chemical(s), and interactions of the biologically eﬀective
moiety with the target tissue macromolecules [2]. Critical
data gaps exist in these cause-eﬀect relationships. In the
absence of a complete set of data, in silico/computational
tools can help ﬁll the data gaps [3–8]( Figure 1). In
silico modeling employs the mathematical know-how and2 Journal of Toxicology
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Figure 1: Application of in silico models in establishing the cause
and eﬀect relationship.
the computer science advances to evaluate exposures and
sometimes to predict risk posed by chemicals.
Several in silico models are used to track the movement
of chemicals through the environment and through the
humanbody.Physiologicallybasedpharmacokinetic(PBPK)
models are a family of such tools; their potential applications
in human health risk assessment have stirred considerable
interest. The salient feature of PBPK models is that through
simulation they can approximate the kinetic behavior of
chemical(s). The models are actually designed to integrate
the physical and biological characteristics of a chemical with
the physiological happenings in the body to estimate internal
dose in target tissues/organs.
In 1995, a group of experts were brought together by
ATSDR to advice on the application of computational tools
for human risk assessment of toxic substances [9]. Since
then, in silico modeling has been applied, where possible, for
hazard identiﬁcation and to determine internal dose through
quantitative structure-activity relationship (QSAR), PBPK,
PBPK/pharmacodynamic, and biologically based dose-re-
sponse (BBDR) modeling [10–15].
Engaged academics, stakeholders, and other interested
parties have supported modeling projects, advancement of
model development, and model applications. We have high-
lighted in this paper selected PBPK model applications at the
Agency for Toxic Substances and Disease Registry (ATSDR)
and National Center for Environmental Health (NCEH),
Centers for Disease Control and Prevention (CDC), that led
to derivation of minimal risk levels (MRLs); risk assessment
of mixtures; assessment of occupational exposures; site
speciﬁc assessment; interpretation of human biomonitoring
data.
2. PBPK Modelingand
MinimalRiskLevels (MRLs)
Minimal risk levels (MRLs) are estimates of daily human
exposure to a hazardous substance at or below which that
substance is unlikely to pose a measurable risk of harmful
(adverse), noncancerous eﬀects. MRLs are calculated for an
exposure route (inhalation or oral) over a speciﬁed period
(acute, intermediate, or chronic). MRL calculations are typi-
cally based on toxicity studies conducted with speciﬁc routes
of administration. From such data no observed adverse
eﬀect levels (NOAELs) or lowest observed adverse eﬀect
levels (LOAELs) are identiﬁed and adjusted for associated
uncertainties.SometimesdatamightbeappropriateforMRL
derivation from one route but not from another. Database
gaps or lack of suitable experimental studies prevent using
this empirical approach to derive MRLs for all priority
pollutants and for all routes of potential exposure. To
circumvent this problem, we examined the potential use of
PBPK modeling by studying methylene chloride (MC) and
trichloroethylene (TCE). PBPK models were available, and
MRLs were derived for both these chemicals of interest [16–
19]. We used PBPK models to derive each MRL using the
study that had provided the basis for the then-current MRL.
In general, the MRLs derived using PBPK models were
somewhat higher compared with those derived using the
traditional approach. For MC, PBPK-derived MRLs tended
to be higher (ratio of 2 to 15) for both inhalation and oral
exposure.ForTCE,PBPK-derivedMRLstendedtobeslightly
higher (ratio of 1 to 4) for inhalation exposure but yielded
m u c hl o w e rM R L s( r a t i oo f0 . 0 3t o0 . 2 0 )f o ro r a le x p o s u r e .
These diﬀerences were chemical, exposure route-dependent,
and varied as a function of dose metric used. The general
conclusion of this exercise was that a full PBPK model may
not be necessary to derive an MRL—a good understanding
and application of basic pharmacokinetic principles might
suﬃce [16].
3.PBPK/PD Modelingof Mixtures
Exposure to multiple chemical or nonchemical stressors is a
fact of life. Recently, more attention has been paid to the risk
assessment of such exposures [1]. Because PBPK models can
incorporate pharmacodynamic characteristics of a chemical,
they can be employed in cumulative risk assessment for
exposure to multiple chemicals [20]. As methods of chemical
mixture risk assessment have evolved during the past two
decades,theyhaveundergonedrasticchanges.Initially,single
chemical methods, with slight modiﬁcations, were used to
evaluate simple mixture toxicities. Then, speciﬁc methods
were developed to advance these methods further. These,
in turn, were followed by the ﬁrst generation of PBPK
modeling approaches. Now, they are being replaced by the
more advanced second-generation PBPK/PD models. From
the ﬁrst generation’s evaluation of simple mixtures to the
second generation’s evaluation of more complex mixtures,
the development process has gone through diﬀerent phases.
Today’s sophisticated models allow integration of concurrentJournal of Toxicology 3
exposure to multiple chemicals through integrating cellular
and molecular biology information of the component chem-
icals and available mechanistic data [21].
If more than one chemical enters the body, a potential
arises for interactions among chemicals, their metabolites,
and the biological molecules/systems. Interaction threshold
(IT) is deﬁned as combined total dose of chemicals at which
interactions become signiﬁcant in terms of joint toxicity of
a mixture. In most cases, experimental determination of
low-dose interaction thresholds is economically infeasible—
it needs a large number of laboratory animals. Instead,
researchershaveusedanempiricalweight-of-evidencemeth-
odology to evaluate binary interactions [22]. This methodol-
ogy incorporates a “bottom-up” approach to evaluate multi-
component mixtures [22, 23].
If, however, appropriate data are available, PBPK/PD
modeling actually is better than any other method to sim-
ulate various exposure scenarios and to study interactions.
These models can also address episodic or pulse exposures.
We studied interactions between two organophosphates:
chlorpyrifos and parathion [24, 25]. They are both potent
pesticides found together in the environment, have similar
metabolic pathways, and the parent chemicals, and their
respective metabolites cause toxicity by inhibition of acetyl-
cholinesterase (AchE). Chlorpyrifos is rapidly desulfurated
byCYP4503A4and2D6tochlorpyrifos-oxon.Chlorpyrifos-
oxon is 300 to 400 times more potent at inhibiting rat
brain AChE than is chlorpyrifos. Parathion is desulfurated
in the liver by CYP450 3A4, 3A5, 1A2, and 2D6 to paraoxon.
Paraoxon is also a much more active inhibitor of AChE than
is its parent. The same isoenzymes—P450, 3A4, and 2D6—
are involved in the metabolism of both chemicals to the oxon
that inhibits AChE.
Thus, to evaluate the PK and PD interactions between
chlorpyrifos and parathion, we developed a mixture
PBPK/PD model that comprised four individual submodels
(chlorpyrifos, chlorpyrifos-oxon, parathion, paraoxon) [25].
The two parent models were linked to their metabolite
models through the liver compartments (Figure 2). The
predicted metabolite concentrations in blood were linked
to a PD model for AChE kinetics, where the competition
for cholinesterase occurs. Model simulations indicated that
for each chemical, additivity takes place at oral dose levels
below 0.08mg/kg. At higher doses, antagonism by enzy-
matic competitive inhibition occurs. We determined the
interaction threshold by comparing the levels of simulated
mixture response with levels anticipated from the individual
response addition. In this modeling exercise, we showed that
PBPK/PD modeling can improve experimental study design
and can help risk assessors to quantify mixture risks for low-
dose exposures.
Still,foramixturethatcontainsalargenumberofchemi-
cals,a“bottom-up”approachcouldbetediousandimpracti-
cal. Petroleum hydrocarbon mixtures such as gasoline, diesel
fuel, aviation fuel, and asphalt liquids typically contain hun-
dreds of compounds. These compounds include aliphatic
and aromatic hydrocarbons within a speciﬁc molecular
weight range and sometimes lesser amounts of additives.
And they often exhibit qualitatively similar pharmacokinetic
(PK) and pharmacodynamic (PD) properties. Nevertheless,
some components do exhibit speciﬁc biological eﬀects, such
as methyl t-butyl ether and benzene in gasoline. One of the
potential pharmacokinetic interactions of many components
in such mixtures is inhibition of the metabolism of some
components. Due to the mixtures’ complexity, a quantitative
description of the pharmacokinetics of each component has
not been available, particularly in the context of diﬀering
blends of these mixtures.
Consequently, we developed a PBPK modeling approach
to describe the kinetics of whole gasoline [26]. The approach
simpliﬁes the problem by isolating speciﬁc components for
which a description is helpful and by treating the remaining
components as a single, lumped chemical. In this manner,
the eﬀect of the nonisolated components (i.e., inhibition)
is taken into account. As previously shown for simple
mixtures, this gasoline model was developed by linking
at the binary level individual PBPK models through the
liver compartment—where competitive inhibition of hepatic
metabolism occurs. During gas-uptake kinetics experiments
in rats exposed to whole gasoline, kinetics data were used
for the single chemicals, for simple mixtures of the isolated
chemicals, and for the isolated and lumped chemicals.
While some sacriﬁce in model accuracy occurs with a
chemical-lumping approach, such a model still aﬀords a
good representation of the kinetics of ﬁve isolated chemicals
(n-hexane, benzene, toluene, ethylbenzene, and o-xylene)
during exposure to various levels of two diﬀerent gasoline
blends. When appropriate kinetics data are available for
model development, the approach could be applicable to
other hydrocarbon mixtures.
4.ABiologically BasedDose-Response
(BBDR) Model of
Hypothalamic-Pituitary-ThyroidAxis
Some environmental chemicals aﬀect endocrine function.
Even at very low levels, these chemicals could alter hormone
systems. The hypothalamic-pituitary-thyroid (HPT) axis
controls many physiologic functions, including metabolism,
development, and reproduction. A biologically based dose-
response (BBDR) model for adult rats includes submodels
for dietary iodide, thyroid-stimulating hormone (TSH),
and the thyroid hormones thyroxine (T4) and 3,5,3-t r i -
iodothyronine (T3) [27, 28]. The independently developed
individual submodels were linked together to form the
endogeneous BBDR-HPT axis model. The resultant model
incorporates key biological processes, including
(1) theinﬂuenceofT4onTSHproduction(theHPTaxis
negative feedback loop),
(2) stimulation of thyroidal T4 and T3 production by
TSH,
(3) TSH upregulation of the thyroid sodium (Na(+))/io-
dide symporter,
(4) recycling of iodide from metabolism of thyroid hor-
mones.4 Journal of Toxicology
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Figure 2: A schematic diagram of the physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model of acetylcholinesterase
(AchE) inhibition by binary mixtures of chlorpyrifos, parathion, and their metabolites: chlorpyrifos-oxon and paraoxon.
The model was calibrated to predict steady-state concentra-
tions of iodide, T4, T3, and TSH for the euthyroid rat, whose
dietary intake of iodide was 20µg/day. Then, the model was
used to predict perturbations in the HPT axis caused by
insuﬃcient dietary iodide intake. Simulation results were
compared with experimental ﬁndings. The BBDR-HPT axis
model was successful in simulating perturbations in serum
T4, TSH, and thyroid iodide stores for low-iodide diets.
When dietary iodide intake becomes insuﬃcient to sustain
the HPT axis, the model simulations show a steep dose-
response relationship between dietary iodide intake and
serum T4 and TSH. This BBDR-HPT axis model might link
with PBPK models for thyroid-active chemicals to evaluate
and predict dose-dependent HPT axis alterations based on
hypothesized modes of action.
5.PBPK Modelingin
Occupational ExposuresStudies
In another study, we examined the potential toxicity from
coexposure to three CNS depressants: toluene, ethylbenzene,
and xylene were evaluated under resting and working
conditions [29]. Under OSHA and American Conference
of Governmental Industrial Hygienists (ACGIH) guidelines,
the mixture formula (unity calculation) provides a method
for evaluating exposures to mixtures of chemicals that cause
similar toxicities [30]. According to the formula, if exposures
are reduced in proportion to the number of chemicals
and their respective exposure limits, the overall exposure
is acceptable. Most of the occupational exposure limits are
derived from studies of resting humans or animals. But thisJournal of Toxicology 5
approach assumes that responses are additive. To determine
the additivity assumption’s validity, unity calculations were
performed for a variety of exposures to toluene, to ethyl-
benzene, to xylene, or to all three. In the calculation, the
concentration of each chemical in blood was used rather
than the inhaled concentration. The blood concentrations
were predicted using a validated PBPK model to allow
exploration of a variety of exposure scenarios. At rest,
a modest overexposure—2.9 to 4.6 times—occurs due to
pharmacokinetic interactions. But the study showed that
workers with higher activity might experience a signiﬁcantly
higherabsorbeddosethatcouldresultin87%higherinternal
doses.Thisstudyshowedtheimportanceofworkload’seﬀect
on internal chemical doses.
6. Site-SpeciﬁcAssessment Integrating
PBPK/QSAR Modeling
In a highly contaminated residential area, total polychlo-
rinated biphenyls (PCBs) soil levels ranged from 17.4 to
840mg/kg—much higher than the maximum soil level of
1.5mg/kg reported nationally [31]. The national average
range of PCBs in serum is 4–7µg/L, but the serum levels
of some of its residents ranged between 76.3 and 187.5µg/L
[10]. The major human exposure to PCBs is through
ingestion of contaminated food. We wanted to determine
whether soil ingestion contributed to these higher levels
in the serum of area residents. PBPK models of the 25
most common PCB congeners were developed based on a
published method [32]. Partition coeﬃcients and metabolic
constants for the models were determined using published
QSAR procedures [33, 34].
The models were then used to estimate the contribution
of these 25 PCB congeners through soil ingestion to the
levels of serum PCBs. PBPK simulations were run using
a soil ingestion default rate of 50mg/day for a lifetime
exposure scenario. Simulations using average national soil
levels showed that only 0.6% of the total PCBs levels are
from soil. Thus, nationwide soil ingestion was not a major
contributor to serum blood levels. To conﬁrm this in the
contaminated area residents, a probabilistic distribution for
PCB blood levels was derived based on the actual PCB
soil measurements of the area. The distribution was then
applied to the 25 PBPK models to derive a distribution of
predictedtotalPCBsinbloodforlifetimeexposurescenarios.
The derived distribution of blood levels was superimposed
on the actual distribution of measured serum levels. The
distribution of actual blood levels for 9 out of 10 persons fell
within the modeled exposure range, while the mean of the
actual blood levels distribution fell within the 2-percentile,
lower end of the simulated curve (Figure 3).
Thus, in this community, soil did not appear to con-
tribute signiﬁcantly to serum levels. Because of lack of actual
exposure data of the community, however, the simulations
were run on default exposure assumptions. Dietary intake
(e.g., ﬁsh) or inhalation could be the alternative source of
PCBs serum levels. These types of PBPK modeling studies
PBPK model simulation of the
distribution of blood levels as a
function of PCB in soil. The soil
distribution was assumed to be
normal with min = 17.4
and max = 840ppm
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Figure 3: The distribution of actual levels of total PCBs in blood
near a waste site.
help us determine relative contribution of environmental
media to the overall internal doses of chemicals.
7.HumanPBPKTool Kit Development:
The GeneralApproach
To better serve health assessors and increase their use, we
are developing a “human PBPK model toolkit” to assist
with site-speciﬁc health assessments [35–37]. This toolkit
will comprise a series of published models coded in Berkeley
Madonna—a common simulation language [36]. Ultimately
a Web linkage to a PBPK database will be available where
health assessors and other related health workers can access
easily many diﬀerent models for use in assessment activities.
At the outset, we conducted literature review to iden-
tify available human PBPK models for the chemicals of
interest. Following literature searches of human health-
related databases such as Medline, Toxline, and PubMed, we
identiﬁed hundreds of PBPK models. These models varied
in their complexity based on the scientiﬁc understanding of
the chemistry, biological behavior, and insights gained into
the mechanism(s) or mode of action of a given chemical’s
toxicity. Thus, the models contained diﬀerent numbers of
compartments (e.g., liver, kidney, and other organs). Often
the compartments were designed for parent chemicals, but
some included metabolite(s). The criteria we used for model
selectionincludedcriticalscientiﬁcissuessuchasthenumber
of datasets used to calibrate and evaluate the model, the
model’s maturity (number of predecessor models from
which the model was derived), and the author’s experience.
Currently, the toolkit includes models that are at various
stages of development for environmental contaminants,
including volatile organic compounds (VOCs) and metals
[12, 13, 37].
Wealsodevelopedageneric7-compartmentVOCmodel;
it consists of blood, fat, skin, kidney, and liver, rapidly and
slowly perfused tissue compartments, and a gas exchange6 Journal of Toxicology
compartment [37]. We included these compartments in the
model based on their use in previously published PBPK
models [38–43]. The generic VOC PBPK model can be used
for six VOCs:
(i) benzene (BEN),
(ii) carbon tetrachloride (CCl4),
(iii) dichloromethane (DCM),
(iv) perchloroethylene (PCE),
(v) trichloroethylene (TCE),
(vi) vinyl chloride (VC).
All compartments were described as well mixed and ﬂow
limited. We obtained chemical-speciﬁc and biochemical
parameters for the model from published literature [41–
48]. The model code allowed simulation of three routes of
exposure, either individually or simultaneously: inhalation,
oral ingestion, and dermal absorption. Due to the lack of
available published human datasets, we did not conduct a
comparison of the generic model predictions for dermal
route. In the current model version, we also did not include
original-model simulations for metabolites and metabolite
data. Nevertheless, a critical future improvement for this
model’s postscreening use is incorporation of metabolite
information, particularly when metabolite(s) mediate toxi-
city.
Our ﬁrst test of the model’s applicability was to compare
the published human kinetic data for each VOC with the
corresponding published model predictions. To test further
the model’s reliability, we calculated the area under the
concentration curve (AUC) for blood or exhaled breath for
each VOC using both our generic and original model. For
each kinetic time course dataset, we also calculated the mean
of the sum of the squared diﬀerences (MSSDs) between
model prediction and observation. MSSD was computed
by squaring the diﬀerence between a measured data point
and the value of the simulation at the corresponding time.
Then, the summed squares were divided by the number of
data points. The MSSD was thus determined for both the
published model and for our generic VOCs model [37].
For each of the speciﬁc VOCs, we used the VOC PBPK
model to estimate the blood concentrations for the available
minimal risk levels (MRLs) values [49–54]. We repeated
this process for each VOC for which biomonitoring data
on human blood levels were available from the National
Health and Nutrition Examination Survey (NHANES) [55].
Steady-state VOC concentrations in venous blood were
then compared with NHANES data using these simpliﬁed
assumptions about exposure frequency and duration. If the
measured NHANES blood levels were below those estimated
from the simulations, the exposures would be regarded as
“safe” [37].
We also reviewed published human metals PBPK models
for arsenic, mercury, and cadmium [56–61]. We selected the
best model available based on performance, accuracy, and
reproducibility and recoded them using Berkeley Madonna
[36]. We took from the literature human physiological
and chemical-speciﬁc parameters describing the absorption,
distribution,andbloodandtissuepartitioningofAs,Hg,and
Cd. The PBPK models allow simulation of diﬀerent routes of
exposure, either individually or simultaneously.
A published Cd toxicokinetic model [59–61] describes
aggregatedlung,liver,kidney,blood,andothertissues.Intake
by oral and inhalation routes are transferred to an uptake
pool that distributes to three blood compartments [61]. The
modelpredictedtheurinaryconcentrationsofCdconsidered
a surrogate for body burden in assessing health risk from
exposure, including the sex- and age-stratiﬁed geometric
urinarymean.Thismodelwasusedtopredictthecreatinine-
corrected urinary Cd concentrations among females and
males from the Fourth National Report on Human Exposure
to Environmental Chemicals [55].
We recoded a human PBPK model for arsenic. It consists
of interconnected submodels for inorganic arsenic and its
metabolites, monomethyl arsenic (MMA), and dimethy-
larsenic (DMA) [56]. It includes compartments for lung,
liver, GI tract, kidney, muscle, brain, skin, and the heart.
Single or continuous oral exposures to inorganic arsenic in
the +3 or +5 valence state or exposures via drinking water
were simulated. The recoded model adequately simulated
experimental human data found in the published literature
[56]. Using a visual comparison, the model performance was
in good agreement with the original model. We evaluated
performance by calculating values for percent median abso-
lute performance error (MAPE %), median performance
error (MPE %), and root median square performance error
(RMSPE %) based on estimates of performance error (PE)
[12].
Werecodedahumantoxicokineticmodelformethylmer-
cury based on the Carrier et al. model [12, 57, 58]. The
model consists of a total body compartment. By a ﬁrst-
order process, methylmercury enters this compartment from
the GI tract. The amount of methylmercury in blood
is proportional to that in the total body compartment.
The recoded model reproduced all the simulations of the
original model [57, 58]. By visual comparison, the model
performance was in good agreement with the original
model. We evaluated the model performance by calculating
a value for percent median absolute performance error
(MAPE %), median performance error (MPE %), and
root median square performance error (RMSPE %) based
on estimates-of-performance error (PE). The model could
simulate and could accurately predict the available total
body burden of mercury experimental data. The model
predictions were similar to those observed experimentally
andfoundinpublishedliterature.Overall,thecurrentmodel
could integrate those various experimental data that are
critical determinants of methylmercury kinetics. The current
model duplicates the time courses of various tissue burdens
for diﬀerent dose regimens and exposure scenarios.
8. PBPK: Biomonitoring Data and
Its Interpretation
Several population-representative biomonitoring programs
are underway in Canada, California, Asia, and Europe.Journal of Toxicology 7
These biomonitoring programs are similar to CDC’s Na-
tional HealthandNutrition Examination Survey (NHANES)
that provides representative data for the United States. For
risk managers, the growing availability of such data for
hundreds of chemicals provides an opportunity as well as a
challenge. To address the interpretation of such data, several
alternative methods have been proposed, such as reverse
dosimetry [62] and biomonitoring equivalents (BEs) [63].
The reverse dosimetry approach employs PBPK models
as a tool; this tool interprets NHANES data to estimate
the intake dose or external environmental concentration
b a s e do nam e a s u r e dt i s s u ec o n c e n t r a t i o n[ 64–68]. We used
the chloroform PBPK model [48] in combination with a
mass transfer model [69] that describes the transfer of
volatile organic chemicals (VOCs) from water to air during
showering—an event that contributes signiﬁcantly to VOC
inhalation exposure. We incorporated exposure contribu-
tionsfrommultiroutesand-sourcesintothepublishedPBPK
model [48]. This integrated model was used to predict
chloroformconcentrationsinbloodandexhaledbreathfrom
multiroute exposure to chloroform in the general popula-
tion. MATLAB Simulink, the graphical simulation tool (The
Math-Works,Inc.,Natick,MA)wasusedfortime-courseand
dose-response simulations, with a Monte Carlo sensitivity
analysis. The predictive ability of this combined model was
evaluated with three published studies that provided exhaled
breath or blood chloroform concentrations. The studies also
gave the most complete descriptions of how the volunteers
were exposed and when the exhaled breath or blood samples
were collected. To make it as close to reality as possible, we
varied—together with other parameters in the model—the
time of blood and exhaled breath samples collection and
starting time of showering and water drinking. We ran the
model for 10,000 iterations.
Reverse dosimetry was carried out by performing Monte
Carlo analysis using appropriate varied timing of sampling
and exposure. A reference chloroform concentration in
water (1µg/L) was then used to predict the distribution of
chloroform concentrations in blood (pg/mL). The values
thus obtained were then inverted to obtain a distribution
of an “exposure conversion factor” (ECF) in (µg/L in
water)/(pg/mL in blood). The distribution of the ECF can
be multiplied by any observed chloroform concentrations in
blood to estimate a distribution of chloroform concentra-
tions in water to which a person might have been exposed.
Our original assumption was that a simple structured
PBPK model was adequate—a complex model increased the
number of parameters and associated uncertainties. On the
contrary, we found that a comprehensive exposure regimen
was needed to aggregate all major contributing factors,
including spatial and temporal proﬁles of chloroform in
water,chloroforminambientair,humanactivities,andwater
consumption patterns.
Showering was shown to yield much higher chloroform
concentrations in blood than did water drinking—a con-
clusion consistent with previous experimental study. Still,
that chloroform metabolites induce cytolethality in target
tissues but not the parent compound is well known. Despite
chloroform’s higher concentration in blood after showering
than after water-drinking exposure, that more chloroform
is metabolized (ﬁrst-pass) after water drinking exposure is
possible and may exert more toxicity compared with shower-
ing exposure. This experience shows that only by integrating
biomonitoringandPBPK/PDmodelingtechniquesintoboth
exposureandriskassessmentscanweobtainamorescientiﬁc
basis for regulatory decisions that protect the public health.
Biomonitoring equivalents (BEs) are also used to inter-
pret exposures [63, 70–72]. BEs estimate the concentration
of a chemical or its metabolite in a biological medium
consistent with an existing exposure guidance value such
as a tolerable daily intake, minimal risk levels, or reference
dose. The BE approach integrates available pharmacokinetic
data necessary to convert, in a biological medium, a current
exposure guidance value into an equivalent concentration. A
range of pharmacokinetic data and approaches not limited
to PBPK modeling is used to derive BE values. If human
pharmacokinetic information is available, a target external
dose is converted into the corresponding expected internal
dose (concentration of parent compound or metabolite
in blood or urine or both) in humans. Alternatively, if
pharmacokinetic data are available in the animal species
used in the study, those data provide the point of departure
(POD) on which the exposure guidance value is based. The
internal dose is then estimated in the animal at the POD.
The appropriate uncertainty factors (UFs) then correspond
tothoseusedinthederivationoftheexposureguidancevalue
and are applied to derive a BE.
Wealsocollectedriskassessment-basedchronicexposure
reference values such as reference doses (RfDs), reference
concentrations (RfCs), tolerable daily intakes (TDIs), cancer
slope factors, and key pharmacokinetic model parame-
ters for 47 VOCs [71]. Using steady-state solutions to a
generic PBPK model structure, chemical-speciﬁc, steady-
state venous blood concentrations were estimated across
chemicals associated with unit oral and inhalation exposure
rates and with chronic exposure at the identiﬁed expo-
sure reference values. The thus-derived screening values—
estimates of average blood concentrations—were then con-
sistentwithwhatwouldbeexpectedinatypicaladulthuman
exposed at steady-state to the identiﬁed reference values.
These screening values might be rough. But they do allow
comparison of measured blood VOC concentrations to a
benchmarkconsistentwithexistingriskassessmentsforthese
compounds rather than bright lines separating safe from
unsafe exposure levels. Such a comparison can assist in the
integration of these biomonitoring data into risk assessment,
management, and prioritization decisions. Thus, in this
instance, fully developed PBPK models, while useful, are not
required [63, 71]. The BE values can be used as screening
levels and can also be used to classify chemicals into low,
medium, and high-priority categories for risk assessment
followup.
9. Conclusions
After decades of toxicity testing, the emerging reality is that
routine toxicity testing cannot ﬁll the large data gaps that8 Journal of Toxicology
daily confront data generators (experimental scientists) and
data users (assessors/regulators). And recent years have seen
a shift away from studying health eﬀects in whole animals.
This shift also serves to reﬁne, reduce, and replace animal
useasthebasisofICCVAMlegislation.Infact,morerecently,
this shift has spurred the use of human in vitro systems and
high-throughput data generation.
As new chemicals and contaminants enter the environ-
ment, reliance on in silico modeling will increase. PBPK,
PBPK/PD, BBDR models are tools that will help establish
the cause-eﬀect relationship—the basic tenant of risk assess-
ment. The chief advantage of these tools, particularly the
PBPK models, is their predictive power. It is this power that
ﬁlls database gaps through simulations based on meticu-
lously articulated scientiﬁc facts.
Many scientiﬁcally accurate and advanced PBPK models
have been developed to evaluate carcinogenic and non-
carcinogenic health eﬀects. They are capable of route-to-
route, exposure duration, interspecies, and other extrapo-
lations commonly used in risk assessment. But health risk
assessors—most of whom have limited experience with
simulation software—are uncomfortable with the multiple
simulation languages such as MatLab, Simusolve, and AcslX
used to code those simulations. This limitation also restricts
ﬁeld application of the models in public health practice.
Even experienced PBPK modelers, due to the lack of key
information or equations, sometimes face problems when
reconstructing published PBPK models for application. For
these reasons, risk managers, decision makers, and the risk
assessment community have been hesitant to adopt them.
Having the models in easier-to-use form capable of solving
real life problems will greatly increase their value and will
help integrate technological and scientiﬁc advances into
decision making.
PBPK models can also be useful in targeted research.
They can estimate target organ concentrations of chemicals
and integrate such information to predict whole-animal
exposures. Because they are designed to determine the
internal tissue concentration of a chemical from multiple
exposure routes, they can help to determine the appropriate
dose in target organs that could be used in in vitro toxicity
testing systems. Combining in vitro pharmacokinetics and
pharmacodynamics information could produce a concentra-
tionsuitableforriskassessment[73,74].Onceidentiﬁed,the
in vivo exposure corresponding to the in vitro concentration
could be estimated through in vitro-in vivo extrapolation
[75,76].Developingappropriatedosemetrics,incorporating
mode of action, and other chemical speciﬁc information
could predict in vivo dose response curves from in vitro
data [66, 76, 77]. But such extrapolations as determination
of human external exposures to VOCs based on measured
blood levels need careful assessment of the interval between
exposure and sampling time since the latter only represent
the concentration at the sample time and are a product
of complex exposures from multiple routes and multiple
sources [66, 78–80].
Hypothetically, reverse dosimetry shows the opposite
could also be true [62, 64, 66]. That is, if we know the in
vitro concentration that causes adverse eﬀect(s) at a cellular
or organ level, we could use these models to extrapolate to in
vivotissuelevelandultimatelytoahuman-allowableexternal
dose. Some advances are being made towards this goal
by integrating human dosimetry insights gained through
in vitro studies and high throughput screening [81, 82].
Employing computational techniques and new simulation
platforms, it has been shown that estimated oral equivalents
could then be compared with allowable human exposures
through environmental media.
In summary, though these models have not yet realized
their potential, in silico toxicology is a growing ﬁeld that
will produce new and innovative computational tools. High-
throughput screening and in vitro testing are changing
toxicology testing strategies. In fact, such tests are helping to
create the next generation of computational tools. But devel-
opment of in silico tools should continually consider the two
critical qualities necessary for the end-user—ease of use and
accessibility. Training, increased transparency, and enhanced
application could also help in-silico tools’ acceptance as a
real-life decision making tool. Finally, translational research,
such as the development of the human PBPK toolkit, could
further contribute to in-silico tools’ accessibility and ease of
use.
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